Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 11/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | YAP1 | P46937 | 1/20 | 0.39 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.39 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.39 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24209504 | 0.83 | MAPT (0.43) | ACACBMAPTYAP1TEAD4TEAD2 | |
| SCHEMBL22014825 | 0.83 | SMN1; SMN2 (0.38) | MAPTSMN1; SMN2 | |
| SCHEMBL22014827 | 0.83 | KMT2A (0.46) | MAPTSMN1; SMN2 | |
| SCHEMBL22014833 | 0.83 | RAB9A (0.40) | MAPTSMN1; SMN2 | |
| SCHEMBL22014801 | 0.82 | HTR7 (0.43) | ACACBMAPTPKMSMN1; SMN2 | |
| SCHEMBL24209212 | 0.82 | MAPT (0.50) | MAPTYAP1TEAD4TEAD2FKBP1A | |
| SCHEMBL24209495 | 0.80 | ALDH1A1 (0.35) | ACACBMAPTYAP1TEAD4TEAD2 | |
| SCHEMBL24209170 | 0.80 | ALDH1A1 (0.35) | ACACBMAPTYAP1TEAD4TEAD2 | |
| SCHEMBL24209211 | 0.80 | ALDH1A1 (0.35) | ACACBMAPTYAP1TEAD4TEAD2 | |
| SCHEMBL22015282 | 0.80 | ALDH1A1 (0.36) | MAPTYAP1TEAD4TEAD2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-01-20 | — | — | US | disclosed |
| WO-2020099886-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017516-A1 | LOX INHIBITORS | LOXL1, LOX, LOXL2 | ACACB 818/4885MAPT 4629/4885YAP1 1547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.